Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Breast Neoplasms 3Pancreatic Adenocarcinoma 2Stomatitis 1Radiation Fibrosis Syndrome 1Peripheral Nervous System Diseases 1Neuroma, Acoustic 1Neoplasms 1Inflammation 1Hypertension 1Glioblastoma 1Fibrosis 1Fallopian Tube Neoplasms 1Coronavirus Infections 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Camurati-Engelmann Syndrome 1COVID-19 1Brain Neoplasms 1

Interventions

Gemcitabine 295Fluorouracil 82Oxaliplatin 81130-nm albumin-bound paclitaxel 68Capecitabine 60Leucovorin 56Albumin-Bound Paclitaxel 54Radiotherapy 51Irinotecan 44Taxes 37Cisplatin 36Erlotinib Hydrochloride 34Radiosurgery 33pembrolizumab 29Docetaxel 27S 1 (combination) 26Bevacizumab 23folfirinox 22Nivolumab 21Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Cetuximab 17irinotecan sucrosofate 16Radiation 16Drug Therapy 15Surgical Procedures, Operative 14Specimen Handling 11Biopsy 11durvalumab 10Paclitaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Neoplasms × Losartan × Clear all
NCT03563248 2025-10-01

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
168 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT05861336 2024-12-27

OVERPASS

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT01821729 2020-09-25

Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Unknown
50 enrolled 11 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡